Home > Publications Database > Neuropsychiatric symptoms and lifelong mental activities in cerebral amyloid angiopathy - a cross-sectional study. > print

001     271971
005     20240929004820.0
024 7 _ |a 10.1186/s13195-024-01519-3
|2 doi
024 7 _ |a pmid:39232823
|2 pmid
024 7 _ |a pmc:PMC11375846
|2 pmc
024 7 _ |a altmetric:167060299
|2 altmetric
037 _ _ |a DZNE-2024-01113
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Dörner, Marc
|0 P:(DE-2719)9002951
|b 0
|e First author
|u dzne
245 _ _ |a Neuropsychiatric symptoms and lifelong mental activities in cerebral amyloid angiopathy - a cross-sectional study.
260 _ _ |a London
|c 2024
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1727079260_8193
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a While several studies in cerebral amyloid angiopathy (CAA) focus on cognitive function, data on neuropsychiatric symptoms (NPS) and lifelong mental activities in these patients are scarce. Since NPS are associated with functional impairment, faster cognitive decline and faster progression to death, replication studies in more diverse settings and samples are warranted.We prospectively recruited n = 69 CAA patients and n = 18 cognitively normal controls (NC). The number and severity of NPS were assessed using the Alzheimer's Disease (AD) Assessment Scale's (ADAS) noncognitive subscale. We applied different regression models exploring associations between NPS number or severity and group status (CAA vs. NC), CAA severity assessed with magnetic resonance imaging (MRI) or cognitive function (Mini-Mental State Examination (MMSE), ADAS cognitive subscale), adjusting for age, sex, years of education, arterial hypertension, AD pathology, and apolipoprotein E status. Mediation analyses were performed to test indirect effects of lifelong mental activities on CAA severity and NPS.Patients with CAA had 4.86 times (95% CI 2.20-10.73) more NPS and 3.56 units (95% CI 1.94-5.19) higher expected NPS severity than NC. Higher total CAA severity on MRI predicted 1.14 times (95% CI 1.01.-1.27) more NPS and 0.57 units (95% CI 0.19-0.95) higher expected NPS severity. More severe white matter hyperintensities were associated with 1.21 times more NPS (95% CI 1.05-1.39) and 0.63 units (95% CI 0.19-1.08) more severe NPS. NPS number (MMSE mean difference - 1.15, 95% CI -1.67 to -0.63; ADAS cognitive mean difference 1.91, 95% CI 1.26-2.56) and severity (MMSE - 0.55, 95% CI -0.80 to -0.30; ADAS cognitive mean difference 0.89, 95% CI 0.57-1.21) predicted lower cognitive function. Greater lifelong mental activities partially mediated the relationship between CAA severity and NPS (indirect effect 0.05, 95% CI 0.0007-0.13), and greater lifelong mental activities led to less pronounced CAA severity and thus to less NPS (indirect effect - 0.08, 95% CI -0.22 to -0.002).This study suggests that NPS are common in CAA, and that this relationship may be driven by CAA severity. Furthermore, NPS seem to be tied to lower cognitive function. However, lifelong mental activities might mitigate the impact of NPS in CAA.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Cerebral amyloid angiopathy
|2 Other
650 _ 7 |a Depression
|2 Other
650 _ 7 |a Lifelong mental activities
|2 Other
650 _ 7 |a Magnetic resonance imaging
|2 Other
650 _ 7 |a Neuropsychiatric symptoms
|2 Other
650 _ 7 |a White matter hyperintensities
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a Cerebral Amyloid Angiopathy: diagnostic imaging
|2 MeSH
650 _ 2 |a Cerebral Amyloid Angiopathy: psychology
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Neuropsychological Tests
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnostic imaging
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: etiology
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Severity of Illness Index
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
700 1 _ |a Tyndall, Anthony
|b 1
700 1 _ |a Hainc, Nicolin
|b 2
700 1 _ |a von Känel, Roland
|b 3
700 1 _ |a Neumann, Katja
|0 P:(DE-2719)2810407
|b 4
|u dzne
700 1 _ |a Euler, Sebastian
|b 5
700 1 _ |a Schreiber, Frank
|0 P:(DE-2719)9000986
|b 6
|u dzne
700 1 _ |a Ulbrich, Philipp
|0 P:(DE-2719)9000797
|b 7
|u dzne
700 1 _ |a Fuchs, Erelle
|b 8
700 1 _ |a Garz, Cornelia
|0 P:(DE-2719)2813207
|b 9
|u dzne
700 1 _ |a Glanz, Wenzel
|0 P:(DE-2719)2811614
|b 10
|u dzne
700 1 _ |a Butryn, Michaela
|0 P:(DE-2719)9001011
|b 11
|u dzne
700 1 _ |a Schulze, Jan Ben
|b 12
700 1 _ |a Schiebler, Sarah Lavinia Florence
|b 13
700 1 _ |a John, Anna-Charlotte
|b 14
700 1 _ |a Hildebrand, Annkatrin
|b 15
700 1 _ |a Hofmann, Andreas B
|0 P:(DE-2719)9000921
|b 16
700 1 _ |a Machetanz, Lena
|b 17
700 1 _ |a Kirchebner, Johannes
|b 18
700 1 _ |a Tacik, Pawel
|0 P:(DE-2719)9002214
|b 19
|u dzne
700 1 _ |a Grimm, Alexander
|b 20
700 1 _ |a Jansen, Robin
|b 21
700 1 _ |a Pawlitzki, Marc
|0 P:(DE-2719)9003204
|b 22
|u dzne
700 1 _ |a Henneicke, Solveig
|0 P:(DE-2719)2813348
|b 23
|u dzne
700 1 _ |a Bernal, Jose
|0 P:(DE-2719)9001989
|b 24
|u dzne
700 1 _ |a Perosa, Valentina
|0 P:(DE-2719)9000985
|b 25
|u dzne
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 26
|u dzne
700 1 _ |a Meuth, Sven G
|b 27
700 1 _ |a Vielhaber, Stefan
|0 P:(DE-2719)2000035
|b 28
|u dzne
700 1 _ |a Mattern, Hendrik
|0 P:(DE-2719)9002178
|b 29
|u dzne
700 1 _ |a Schreiber, Stefanie
|0 P:(DE-2719)2812631
|b 30
|e Last author
|u dzne
773 _ _ |a 10.1186/s13195-024-01519-3
|g Vol. 16, no. 1, p. 196
|0 PERI:(DE-600)2506521-X
|n 1
|p 196
|t Alzheimer's research & therapy
|v 16
|y 2024
|x 1758-9193
856 4 _ |u https://pub.dzne.de/record/271971/files/DZNE-2024-01113%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/271971/files/DZNE-2024-01113.pdf
856 4 _ |u https://pub.dzne.de/record/271971/files/DZNE-2024-01113%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/271971/files/DZNE-2024-01113%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/271971/files/DZNE-2024-01113%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/271971/files/DZNE-2024-01113.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:271971
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002951
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 4
|6 P:(DE-2719)2810407
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9000986
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9000797
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2813207
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2811614
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)9001011
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)9002214
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 22
|6 P:(DE-2719)9003204
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 23
|6 P:(DE-2719)2813348
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)9001989
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 25
|6 P:(DE-2719)9000985
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)2000005
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 28
|6 P:(DE-2719)2000035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)9002178
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)2812631
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-19
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS RES THER : 2022
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:09:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:09:21Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-19
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-19
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-19
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-19
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ALZHEIMERS RES THER : 2022
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-19
920 1 _ |0 I:(DE-2719)1310010
|k AG Schreiber
|l Mixed Cerebral Pathologies and Cognitive Aging
|x 0
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 1
920 1 _ |0 I:(DE-2719)1011103
|k AG Spottke
|l Clinical Research Platform (CRP)
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1310010
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1011103
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21